[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Syndax: When Does the Revenue Ramp Start Covering the Cash Burn Story?

Syndax Pharmaceuticals reports first-quarter 2026 results after market close on April 30, with analysts expecting continued losses but significant improvement from the prior year. The central question is whether the company's two commercial oncology products—Revuforj and Niktimvo—can sustain the revenue momentum that drove 261% year-over-year growth expectations, and whether management can provide a credible path to profitability after last quarter's disappointing miss rattled investor confidence.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for cancer, with two recently launched commercial products: Revuforj for acute myeloid leukemia and Niktimvo for chronic graft-versus-host disease. The company operates primarily in the...

Fundamentals

See More
  • Market Capitalization, $K 1,819,586
  • Shares Outstanding, K 88,201
  • Annual Sales, $ 172,350 K
  • Annual Income, $ -285,420 K
  • EBIT $ -273 M
  • EBITDA $ -284 M
  • 60-Month Beta 0.41
  • Price/Sales 10.80
  • Price/Cash Flow N/A
  • Price/Book 28.24

Options Overview Details

View History
  • Implied Volatility 99.66% (-0.90%)
  • Historical Volatility 40.38%
  • IV Percentile 82%
  • IV Rank 51.66%
  • IV High 150.01% on 10/16/25
  • IV Low 45.85% on 03/12/26
  • Expected Move (DTE 15) 2.92 (14.13%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 70
  • Volume Avg (30-Day) 638
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 13,985
  • Open Int (30-Day) 14,234
  • Expected Range 17.71 to 23.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.58
  • Number of Estimates 6
  • High Estimate $-0.40
  • Low Estimate $-0.77
  • Prior Year $-0.98
  • Growth Rate Est. (year over year) +40.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.37 +1.87%
on 04/29/26
25.53 -18.73%
on 04/06/26
-1.73 (-7.70%)
since 03/30/26
3-Month
19.21 +8.02%
on 02/27/26
25.59 -18.91%
on 03/25/26
+0.44 (+2.17%)
since 01/30/26
52-Week
8.58 +141.84%
on 05/15/25
25.59 -18.91%
on 03/25/26
+6.60 (+46.64%)
since 04/30/25

Most Recent Stories

More News
Syndax: When Does the Revenue Ramp Start Covering the Cash Burn Story?

Barchart Research What to Expect from SNDX Earnings SNDX Generated April 29, 2026 Current Price $20.63 EPS Estimate $$-0.58 Consensus Rating Strong Buy Average Move 10.13% Syndax: When Does the Revenue...

SNDX : 21.02 (+1.89%)
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 21.02 (+1.89%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1,...

SNDX : 21.02 (+1.89%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1,...

SNDX : 21.02 (+1.89%)
Syndax: Q4 Earnings Snapshot

Syndax: Q4 Earnings Snapshot

SNDX : 21.02 (+1.89%)
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025...

SNDX : 21.02 (+1.89%)
Syndax Announces Participation in March Investor Conferences

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 21.02 (+1.89%)
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 21.02 (+1.89%)
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 21.02 (+1.89%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February...

SNDX : 21.02 (+1.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 21.61
2nd Resistance Point 21.31
1st Resistance Point 20.97
Last Price 21.02
1st Support Level 20.33
2nd Support Level 20.03
3rd Support Level 19.69

See More

52-Week High 25.59
Last Price 21.02
Fibonacci 61.8% 19.09
Fibonacci 50% 17.08
Fibonacci 38.2% 15.08
52-Week Low 8.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.